Analysts Hot, Investors Lukewarm On Allos’ Pralatrexate Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Reaction proves mixed to top-line data for antifolate against peripheral T-cell lymphoma.
You may also be interested in...
When An SPA Is Not Enough: FDA Will Consider Response Rate For Allos Drug
The trial supporting the NDA for Allos Therapeutics' peripheral T-cell lymphoma drug pralatrexate was conducted under a Special Protocol Assessment with FDA - but that does not necessarily mean the magnitude of benefit shown will satisfy the agency
When An SPA Is Not Enough: FDA Will Consider Response Rate For Allos Drug
The trial supporting the NDA for Allos Therapeutics' peripheral T-cell lymphoma drug pralatrexate was conducted under a Special Protocol Assessment with FDA - but that does not necessarily mean the magnitude of benefit shown will satisfy the agency
Allos Plans On Speedy NDA Filing For Cancer Drug Pralatrexate
Compound shows response in Phase II peripheral T-cell lymphoma trial.